CVS Caremark (NYSE: CVS) reported Q2 EPS of $0.65, $0.01 better than the analyst estimate of $0.64. Revenue for the quarter came in at $26.6 billion versus the consensus estimate of $26.76 billion.

Sees FY2011 EPS of $2.75-$2.81, versus prior guidance of $2.72-$2.82 and the consensus of $2.78.

UPDATE - from its Q2 conference call: sees Q3 adj-EPS of 66-68c, vs. the consensus of 68c.

Earnings Guidance Hot Guidance